Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival (2012)

Peer-Reviewed Study · Guo L, Bai SP, Zhao L, Wang XH · September 2012

Guo L et al., 2012-09: Randomised trial in 136 patients with advanced NSCLC: astragalus polysaccharide injection added to vinorelbine-cisplatin improved quality of life, fatigue and nausea, but produced no significant difference in response rate or survival.

The objective response rate of was 42.64% in the VC-APS arm and 36.76% in the VC arm. The difference was not statistically significant (P = 0.483). Median survival time was 10.7 and 10.2 months (P = 0.76) in VC-APS arm and VC arm, with 1-year survival rates of 35.3 and 32.4% (P = 0.717), respectively.

Abstract

Guo L et al., 2012-09: Randomised trial in 136 patients with advanced NSCLC: astragalus polysaccharide injection added to vinorelbine-cisplatin improved quality of life, fatigue and nausea, but produced no significant difference in response rate or survival. The clearest later RCT counterweight to the 2006 meta-analysis: QoL gains, no survival gain (median 10.7 vs 10.2 months, P = 0.76). Single-country, single-centre trial; funding and per-author disclosures not carried in the PubMed record. Comparator: same chemotherapy without astragalus. Study type: randomized trial.